Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446899 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 373
- Enrollment target
NCT02446899 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 373 participants.
The verdict
NCT02446899, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 373 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- BIOLOGICAL Anifrolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2018-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446899
The ClinicalTrials.gov registry entry for NCT02446899 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02446899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446899 about?
NCT02446899 is a clinical study titled "Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
What is the current status of trial NCT02446899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 373 participants. The study started on 2015-07-09. Estimated completion is 2018-09-27.
What interventions are being tested in trial NCT02446899?
The interventions under investigation include: Placebo (DRUG), Anifrolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02446899?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.